Q2 EPS Forecast for Akebia Therapeutics Reduced by Analyst

Akebia Therapeutics, Inc. (NASDAQ:AKBA) – Equities research analysts at HC Wainwright lowered their Q2 2026 earnings per share (EPS) estimates for shares of Akebia Therapeutics in a research note issued to investors on Friday, February 6th. HC Wainwright analyst M. Caufield now anticipates that the biopharmaceutical company will post earnings of $0.02 per share for the quarter, down from their previous forecast of $0.04. HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Akebia Therapeutics’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Akebia Therapeutics’ Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.05 EPS, FY2026 earnings at $0.12 EPS, FY2029 earnings at $0.30 EPS and FY2030 earnings at $0.44 EPS.

A number of other research analysts have also commented on AKBA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Akebia Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen cut Akebia Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 28th. BTIG Research reissued a “buy” rating and issued a $5.00 price objective on shares of Akebia Therapeutics in a research note on Tuesday, December 2nd. Finally, Piper Sandler decreased their target price on Akebia Therapeutics from $6.00 to $4.00 and set an “overweight” rating for the company in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Akebia Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $5.60.

Akebia Therapeutics Stock Performance

AKBA stock opened at $1.39 on Monday. The company has a 50-day simple moving average of $1.51 and a 200 day simple moving average of $2.33. The company has a market capitalization of $368.86 million, a P/E ratio of -19.85 and a beta of 0.38. The company has a quick ratio of 1.80, a current ratio of 1.94 and a debt-to-equity ratio of 1.15. Akebia Therapeutics has a fifty-two week low of $1.30 and a fifty-two week high of $4.08.

Insider Buying and Selling at Akebia Therapeutics

In related news, CAO Richard C. Malabre sold 49,524 shares of Akebia Therapeutics stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $1.39, for a total value of $68,838.36. Following the transaction, the chief accounting officer directly owned 299,390 shares in the company, valued at $416,152.10. The trade was a 14.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 3.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Akebia Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its holdings in shares of Akebia Therapeutics by 20.7% in the second quarter. Geode Capital Management LLC now owns 6,074,458 shares of the biopharmaceutical company’s stock worth $22,115,000 after buying an additional 1,043,718 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Akebia Therapeutics by 21.7% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,180,759 shares of the biopharmaceutical company’s stock valued at $4,298,000 after acquiring an additional 210,925 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Akebia Therapeutics in the 2nd quarter valued at approximately $59,000. Assenagon Asset Management S.A. acquired a new position in Akebia Therapeutics in the 3rd quarter worth approximately $1,165,000. Finally, Acadian Asset Management LLC purchased a new position in Akebia Therapeutics during the 2nd quarter worth approximately $4,913,000. Institutional investors and hedge funds own 33.92% of the company’s stock.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company’s lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia’s research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders.

Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach.